Compare Inovio Pharmaceuticals Inc (INO) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Marsh & McLennan Companies, Inc. trades at $181.62 (market cap $87.77B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 983.2× Inovio Pharmaceuticals Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.17% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MRSH | |
|---|---|---|
Market Cap | $89.27M | $87.77B |
Sector | Health | Financials |
52-Week High | $2.87 | $211.21 |
52-Week Low | $1.05 | $157.32 |
Enterprise Value | $60.28M | $108.61B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Marsh (MRSH) trades at $181.79, down slightly (-0.21%) on the day. The stock exhibits a bullish technical trend with strong moving average signals, while fundamentals are solid with consistent revenue growth to $26.98B in 2025 and a robust net income margin of 14.26%. Recent news highlights a 10% dividend increase to $0.99 per share and strategic partnerships expanding its advisory business. The company has beaten earnings estimates for the last three consecutive quarters.
The outlook for MRSH is positive, supported by earnings momentum and shareholder returns, though rising operating expenses and a premium valuation (P/E of 22.77) present near-term risks. Analyst consensus is a 'Hold' with a $203.75 price target, suggesting modest upside potential from current levels, but investor sentiment is tempered by cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
